Congratulations to Pappas portfolio company Aura Biosciences on their positive Phase 1 data!
This afternoon, Aura announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer. Read the full release here: bit.ly/4dZ9Efu